Echo Therapeutics (ECTE) 1.69 $ECTE
Echo Therapeutics in Final Stage of Clinical Research Organization (CRO) Selection
PR Newswire - Thu Jun 02, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that it is in the final stage of selecting a Clinical Research Organization (CRO) for the development of a comprehensive regulatory and clinical strategy for its CGM system. Following its ongoing diligence process, Echo will select a full-service CRO with a global reach and a demonstrated track record of successfully designing and managing clinical trials.
ECTE: 1.69 (-0.21)
Echo Therapeutics, Inc. Announces First Quarter 2016 Financial Results
PR Newswire - Fri May 20, 10:34AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced its financial results for the quarter ended March 31, 2016. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, may be accessed on the SEC's website, www.sec.gov.
ECTE: 1.69 (-0.21)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation into Possible Violations of Delaware Law by Certain Officers and Directors of Echo Therapeutics, Inc.
BusinessWire - Fri May 06, 3:05PM CDT
Levi & Korsinsky announces it has commenced an investigation of Echo Therapeutics, Inc. (NASDAQ:ECTE) concerning possible violations of Delaware law. To obtain additional information about the investigation, go to:
ECTE: 1.69 (-0.21)
Echo Therapeutics Announces Final Closing of Private Placement of $5.1 Million of Convertible Notes and Warrants
PR Newswire - Wed May 04, 3:11PM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive, needle-free continuous glucose monitoring (CGM) and associated technologies, today announced the final closing of a previously announced $5,145,000 private placement financing transaction of convertible notes and warrants. As previously announced, the initial closing of $1,787,000 occurred on January 29, 2016. The second tranche of the financing, or $3,358,000, was subject to the Company obtaining shareholder approval to comply with NASDAQ listing rules. The Company attained shareholder approval at a Special Meeting of Stockholders on April 14, 2016 and the final closing occurred on May 3, 2016.
ECTE: 1.69 (-0.21)
Echo Therapeutics Announces Significant Progress in Key Development Milestones
PR Newswire - Tue May 03, 8:42AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced important advances in its next generation continuous glucose monitoring (CGM) system and its progress toward commercialization in China.
ECTE: 1.69 (-0.21)
Echo Therapeutics Announces Conference Call to Provide an Update on Corporate Milestones
PR Newswire - Thu Apr 28, 7:49AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that it will hold a conference call to provide an update on its progress on upcoming corporate milestones on Wednesday, May 4, 2016, starting at 4:30 p.m. ET.
ECTE: 1.69 (-0.21)
Echo Therapeutics Announces Voting Results of Special Meeting of Stockholders
PR Newswire - Thu Apr 14, 3:30PM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, announced that at the Special Meeting of Stockholders, held today, shareholders approved the issuance of shares of its common stock to comply with NASDAQ listing rules, in connection with the Securities Purchase Agreement, dated January 29, 2016, and other transactions, including the amendment to Company's Certificate of Designations governing the terms of its Series F Convertible Preferred Stock. Shareholder approval at the special meeting was required for the $3,358,000 second closing of the previously announced $5,145,000 private placement financing transaction. As previously announced, the initial closing of $1,787,000 occurred on January 29, 2016.
ECTE: 1.69 (-0.21)
Echo Therapeutics, Inc. Announces 2015 Financial Results
PR Newswire - Wed Mar 30, 4:55PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced its financial results for the year ended December 31, 2015. Echo's Annual Report on Form 10-K, as filed with the SEC, may be accessed on the SEC's website, www.sec.gov.
ECTE: 1.69 (-0.21)
Blood Glucose Testing and Diabetes Management Study 2015
M2 - Tue Feb 02, 10:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/m5ttq8/blood_glucose) has announced the addition of the "Blood Glucose Testing and Diabetes Management" report to their offering. The report has made a survey of selected companies marketing, manufacturing or developing various blood glucose testing and diabetes management supplies throughout the world. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes, among adults across the world. As such, the global market for blood glucose testing products is undergoing a significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, certain segments of the market, such as home testing devices for diabetes management, will exhibit strong growth. What's more, non-invasive testing now represents a major new area for the application of IVD testing. Additionally, direct access testing - or over-the-counter testing, which allows consumers to order tests themselves without visiting a doctor - has emerged as a strong force in the blood glucose testing segment. The purpose of this report is to describe the specific market segments for blood glucose testing and diabetes management. This study reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum or plasma or whole-blood glucose concentrations. Moreover, it examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations. Key Topics Covered: 1. Overview 2. Diabetes 2.1 Demographics of Diabetes 2.2 Understanding the Metabolic Conditions Underlying and Associated with Diabetes 2.3 Economics of Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 3.1 Worldwide Glucose Testing Market 3.2 U.S. Market 3.3 European Market 3.4 Asian Market 3.5 Competitive Situation 3.6 Market Drivers and Restraints 3.7 Market and Product Trends 3.8 Strategic Recommendations 3.9 Competitive Strategies 3.10 New Opportunities in the Professional Blood Glucose Meter Market 3.11 Adjacent Markets 4. Glucose Diagnostic and Monitoring Recommendations 4.1 Diagnosis of Diabetes Mellitus 4.2 Tight Glucose Control in Treating Diabetes 4.3 Recommendations for Glucose Control in Diabetic Patients 4.4 Hypoglycemia and Treatment 5. Glucose Testing Technology Platforms and Consumable Products 5.1 Types of Glucose Determination Technologies 5.2 Enzymatic Reactions Used to Determine Glucose Concentrations 5.3 Development of Blood Glucose Monitors: A Historical Evaluation 5.4 Accuracy and Precision in Glucose Meters 5.5 Key Issues for Glucose Testing Devices 5.6 Limitations of Existing Glucose Testing 5.7 Potential Areas of Improvement in Blood Glucose Meter Performance 5.8 Blood Glucose Reagent Test Strips 5.9 Comparison of Hand-Held Blood Glucose Meters with Clinical Laboratory Glucose Measurements 5.10 Continuous Glucose Monitoring Technology 5.11 Summary of Technologies Being Explored for Non-invasive Glucose Monitoring 5.12 A1c Monitoring Technology 5.13 Fructosamine Test 5.14 Related Reagents and Equipment 6. Glucose Testing Devices on the Market 6.1 Hand-Held Blood Glucose Meters and Strips for Self-testing 6.2 Point of Care Blood Glucose Meters for Professional Use 6.3 Clinical Blood Chemistry Analyzers 6.4 Continuous Glucose Patient Monitoring Systems 6.5 Non-Invasive Glucose Patient Monitoring Systems 6.6 A1c Testing 6.7 New Product Launches 6.8 Blood Glucose Meters, CGMs, and Data Management Software in Development 6.9 Recent Industry Activity 6.10 M&A Activity 7. Business Trends in Glucose Testing 7.1 Drivers of Clinical Glucose Testing 7.2 Competition for Professional POC Glucose Testing 7.3 Healthcare Cost Controls 7.4 Changes in Patient Management 7.5 Regionalization of Laboratory Care 7.6 Satellite Facilities 7.7 Professional Point-of-Care Testing 7.8 Factors Affecting OTC Medical Product Distribution 7.9 Drug Stores Critical to the Diabetic Care Category 7.10 Drivers of OTC and Self-Testing Markets 7.11 Cost Elements of Glucose Self-Testing 7.12 Costs of Doing Business in Europe 7.13 Drivers of European Diagnostics Testing 7.14 Cost Containment in Europe 7.15 Blood Glucose Self-Testing Insurance Coverage and Reimbursement 7.15.1 American OTC Testing and Self-Testing Reimbursement 7.15.2 European Reimbursement 7.16 Reimbursement Challenges 7.16.1 New Medicare Part B 7.17 Managed Care 7.18 Government Regulation of Medical Devices 7.18.1 U.S. Regulations 7.18.2 E.U. Regulations 7.18.3 U.K. Regulations 7.19 Clinical Laboratory Improvement Act (CLIA) 7.19.1 Off-Label/Modified Use of Waived Blood Glucose Monitoring Systems 7.20 FDA Labeling Requirements 7.21 Legal Liability for Glucose Meters 7.22 FDA's Artificial Pancreas Guidance Document 8. Technology Trends 8.1 Improving Today's Over-The-Counter (OTC) Blood Glucose Meters 8.2 Biosensor Technology 8.3 Artificial Pancreas 8.4 Telemedicine 8.5 Non-Traditional Methods for Sample Collection 8.6 Data Management Companies Mentioned - A. Menarini Diagnostics - 9.2 Abaxis, Inc. - Abbott Laboratories - ACON Laboratories - AgaMatrix - Alere - All Medicus - AMS Alliance - Apex Biotechnology Corporation - ARKRAY USA - Bayer - B. Braun Melsungen - Beckman Coulter - Bionime - Bio-Rad Laboratories, Inc. - Cambridge Sensors - Cardiocom - DexCom - Diagnostic Devices/Prodigy Diabetes Care - DiaSys - Diatron - Echo Therapeutics - Entra Health Systems - Fora Care - FIFTY50 Medical, Inc. - Genesis Health Technologies - GenExel-Sein - GlucoPlus - GlySens - Hainice Medical - HemoCue (a Quest Diagnostics company) - Home Diagnostics - Infopia - IN4 Technology - Integrity Applications - International Techidyne Corporation (ITC) - Instrumentation Laboratory Company - i-Sens - Jant Pharmacal - Johnson & Johnson - LabStyle Innovations Corporation - LifeHealth, LLC - Medtronic - Miraculins - Nipro Diagnostics - Nova Biomedical - Polymer Technology Systems - Prodigy Diabetes Care, LLC (formerly Diagnostic Devices, Inc.) - Radiometer Medical - Roche Diagnostics - Senseonics - 77 Elektronika Kft. - Siemens AG - Smiths Group - TaiDoc Technology - Techno Medica Co., Ltd. - Telcare - Tokyo Boeki Medisys - US Diagnostics - Ypsomed Holding - YSI Life Sciences For more information visit http://www.researchandmarkets.com/research/m5...od_glucose About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 38.74 (+1.01), MDT: 84.26 (-0.33), ECTE: 1.69 (-0.21), JNJ: 116.46 (+0.28)
Echo Therapeutics expects up to USD5.1m from sale of convertible notes and warrants
M2 - Tue Feb 02, 3:26AM CST
Medical device company Echo Therapeutics (NasdaqCM:ECTE) reported on Monday the planned sale of up to USD5.145m of secured convertible notes and warrants to purchase common stock in two tranches under a Securities Purchase Agreement with certain institutional and other accredited investors.
ECTE: 1.69 (-0.21)
Echo Therapeutics Announces Entry Into Definitive Agreements for the Sale of up to $5.1 Million of Convertible Notes and Warrants
PR Newswire - Mon Feb 01, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that it entered into a Securities Purchase Agreement with certain institutional and other accredited investors for the sale of up to $5,145,000 of secured convertible notes and warrants to purchase common stock in two tranches. The initial closing of $1,787,000 occurred on January 29, 2016. The second closing of $3,358,000 is subject to shareholder approval. Certain previously issued short-term bridge notes were surrendered as payment of the initial closing purchase price.
ECTE: 1.69 (-0.21)
World Glucose Self-Testing Markets 2016 - Undergoing a Significant Transition Driven by the Advent of New Analytical Technologies
M2 - Wed Jan 13, 6:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/x53b9f/world_glucose) has announced the addition of the "World Glucose Self-Testing Markets" report to their offering. The worldwide incidence of diabetes is dramatically increasing, and it is estimated that 439 million people will have developed the disease by 2030. As such, the global market for blood glucose self-testing products is undergoing a significant transition driven by the advent of new analytical technologies and new recommendations for tight glucose control for monitoring diabetes. In addition, the proliferation of the middle class within developing nations, particularly China and India, has resulted in both a substantial rise in Type 2 diabetes and the financial means to manage the disease. The purpose of this report is to provide a comprehensive analysis of the specific segment of the over-the-counter diagnostics sector known as the glucose self-testing market. The term "self-testing" is used to distinguish it from in vitro diagnostics testing for blood glucose in hospitals, commercial labs and doctor's offices, the so-called "professional" component of the glucose testing market. This study reviews the viable technology drivers and assesses the market dynamics of the glucose self-testing market worldwide. This report also looks at the industry challenges and potential threats, and it makes strategic recommendations for boosting market share. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Self-Testing Technology Platforms and Consumable Products 6. Glucose Self-Testing Meters on the Market: Description of Test Meters 7. Business Trends in the Industry 8. Technology Trends 9. OTC Testing: Critical Issues 10. Current Issues for OTC and Diagnostic Self-Testing 11. SWOT Analysis 12. Company Profiles Companies Mentioned - 77 Elektronika Kft. - A. Menarini Diagnostics - ACON Laboratories - ARKRAY USA, Inc. - Abbott Laboratories - AgaMatrix - Allmedicus Co., Ltd. - Apex Biotechnology Corporation - B. Braun Melsungen - Bayer - Bionime - Cambridge Sensors - Cardiocom - DexCom - Diagnostic Devices/Prodigy Diabetes Care - Echo Therapeutics, Inc. - Entra Health Systems - FIFTY50 Medical, Inc. - Fora Care - Genesis Health Technologies - GlucoPlus - GlySens, Inc. - Google - Hainice Medical - Home Diagnostics - IN4 Technology - Infopia - Integrity Applications - Johnson & Johnson - LabStyle Innovations Corporation - Livongo Health - Medtronic - Miraculins - Nipro Corporation For more information visit http://www.researchandmarkets.com/research/x5...ld_glucose
ECTE: 1.69 (-0.21), JNJ: 116.46 (+0.28), ABT: 38.74 (+1.01), MDT: 84.26 (-0.33)
U.S. Glucose Testing Markets 2016 - Direct Access Testing has Emerged as a Strong Force in the Blood Glucose Testing Segment
M2 - Wed Jan 13, 5:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/p425rm/u_s_glucose) has announced the addition of the "U.S. Glucose Testing Markets" report to their offering. U.S. glucose testing is undergoing a significant transition, driven by new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, several segments of the market, such as home testing devices for diabetes management and point of care (POC) instruments for use in professional settings, will exhibit strong growth. Direct access testing has emerged as a strong force in the blood glucose testing segment, and non-invasive and minimally-invasive testing now represent major new areas for the application of IVD testing. This report describes the specific market segments for blood glucose testing and diabetes management in the U.S. market. It reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum, plasma or whole-blood glucose concentrations. Additionally, this study examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations. Moreover, it analyzes almost all of the companies known to be marketing, manufacturing or developing glucose testing products for the U.S. market. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Testing Technology Platforms and Consumable Products 6. Glucose Testing Devices on the Market 7. Business Trends in Glucose Testing 8. Technology Trends 9. Company Profiles Companies Mentioned - Abaxis, Inc. - Abbott Laboratories - ACON Laboratories - AgaMatrix - Alere - Allmedicus - Amedica Biotech - A. Menarini Diagnostics - Apex Biotechnology Corporation - Arkray - Bayer - B. Braun Melsungen - Beckman Coulter - Bionime - Bio-Rad Laboratories, Inc. - BioTex - Calisto Medical - Cambridge Sensors - DexCom - Diagnostic Devices/Prodigy Diabetes Care - DiaSys - Echo Therapeutics - Entra Health Systems - Fora Care - Freedom Meditech - Genesis Health Technologies - GenExel-Sein - GlucoPlus - GluMetrics - GlySens - GlySure Limited - Grove Instruments For more information visit http://www.researchandmarkets.com/research/p4..._s_glucose
ECTE: 1.69 (-0.21), ABT: 38.74 (+1.01), ABAX: 45.30 (-0.68)
Echo Therapeutics Appoints Elazer Edelman, M.D., Ph.D. to Board of Directors
PR Newswire - Mon Dec 28, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced the appointment of Elazer Edelman, M.D., Ph.D. to its Board of Directors. Currently a professor at MIT and Harvard Medical School, Dr. Edelman is widely recognized for his vision, leadership and significant, long-term contribution to the advancement of technological innovation. Dr. Edelman brings to Echo Therapeutics over 30 years experience in facilitating medical inventions and clinical implementation.
ECTE: 1.69 (-0.21)
The Global Glucose Monitoring Market
M2 - Mon Dec 14, 7:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/gnkzld/the_global) has announced the addition of the "The Global Glucose Monitoring Market" report to their offering. There are many issues facing this industry. Some issues are helping to propel the market; while other issues are retarding growth forward. Issues and trends driving the market for glucose monitoring devices and diabetes management include: - New innovations - Reimbursement challenges - Recalls - Aging of the population - Increasing life expectancy - Healthcare spending trends - Advances in sensors - Health insurance portability - Cost cutting - Healthcare efficiency - Capacity challenges - Growing acceptance of mobile technologies - Other factors. These are discussed at length in the report, as are their role in market growth. In this global report, Kalorama identifies market size and forecast for Traditional Glucose Monitoring and Continuous Glucose Monitoring (CGM) both worldwide and for the following countries and regions: - United States - Germany - France - Italy - UK - Japan - Brazil - Russia - India - China Companies Included: - Abbott Laboratories - AgaMatrix - Arkray, Inc - Bayer Diabetes - Bionime Corporation - DexCom, Inc. - Echo Therapeutics - Entra Health Systems LLC - Fora Care, Inc - Genesis Health Technologies - GlySure Limited - Insulet - Johnson & Johnson - Medtronic - Nipro Diagnostics, Inc - Nova Diabetes Care, Inc. - Oak Tree International Holdings, Inc. - Prodigy Diabetes Care, LLC Roche - U.S. Diagnostics, Inc. Key Topics Covered: Chapter 1 - List of Contributors and Exhibits Chapter 2 - Executive Summary Chapter 3 - Introduction Chapter 4 - Traditional Glucose Monitoring Devices and Diabetes Chapter 5 - Management Market Chapter 6 - Continuous Glucose Monitoring and Sensor Market Chapter 7 - Issues and Trends Chapter 8 - Global Glucose Monitoring Devices and Diabetes Chapter 9 - Management Market and Competitor Analysis Chapter 10 - Corporate Profiles For more information visit http://www.researchandmarkets.com/research/gnkzld/the_global
ECTE: 1.69 (-0.21), JNJ: 116.46 (+0.28), ABT: 38.74 (+1.01), DXCM: 77.49 (-0.02), MDT: 84.26 (-0.33)
Echo Therapeutics, Inc. Announces Third Quarter 2015 Financial Results and Provides Corporate Update
PR Newswire - Mon Nov 16, 3:40PM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced its financial results for the quarter ended September 30, 2015. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, is available by visiting the Investors section of Echo's website at www.echotx.com.
ECTE: 1.69 (-0.21)
Echo Therapeutics' Continuous Glucose Monitoring System to be Profiled on Worldwide Business with kathy ireland® - NEW DAY and TIME!
PR Newswire - Wed Oct 21, 8:27AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring and associated technologies, today announced that it was informed that, due to network scheduling issues, its President and CEO, Scott W. Hollander, is now scheduled to appear on Worldwide Business with kathy ireland, as sponsored programming, on Sunday, October 25, 2015. Echo has accepted this change because it believes that the new day and time will provide increased viewership among key demographics.
ECTE: 1.69 (-0.21)
Echo Therapeutics' Continuous Glucose Monitoring System to be Profiled on Worldwide Business with kathy ireland®
PR Newswire - Wed Oct 21, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring and associated technologies, today announced that its President and CEO, Scott W. Hollander, will appear on Worldwide Business with kathy ireland, as sponsored programming, on Saturday, October 24, 2015.
ECTE: 1.69 (-0.21)
Worldwide Business with kathy ireland Introduces the Exciting Echo Therapeutics Technology for Glucose Monitoring
BusinessWire - Tue Oct 20, 9:20AM CDT
MMP (USA) announces a Worldwide Business with kathy ireland exclusive interview with Scott Hollander, President & CEO of Echo Therapeutics, Inc. Hollander introduces his company with, "Our break-through continuous glucose monitoring system consists of three elements: A micro exfoliator, a sensor and your Smartphone as a monitor. We are applying this exciting capability in multiple markets covering the rapidly growing wearables segments, as well as the outpatient diabetes market."
ECTE: 1.69 (-0.21)
Echo Therapeutics in Final Stage of Clinical Research Organization (CRO) Selection
PR Newswire - Thu Jun 02, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that it is in the final stage of selecting a Clinical Research Organization (CRO) for the development of a comprehensive regulatory and clinical strategy for its CGM system. Following its ongoing diligence process, Echo will select a full-service CRO with a global reach and a demonstrated track record of successfully designing and managing clinical trials.
ECTE: 1.69 (-0.21)
Echo Therapeutics, Inc. Announces First Quarter 2016 Financial Results
PR Newswire - Fri May 20, 10:34AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced its financial results for the quarter ended March 31, 2016. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, may be accessed on the SEC's website, www.sec.gov.
ECTE: 1.69 (-0.21)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation into Possible Violations of Delaware Law by Certain Officers and Directors of Echo Therapeutics, Inc.
BusinessWire - Fri May 06, 3:05PM CDT
Levi & Korsinsky announces it has commenced an investigation of Echo Therapeutics, Inc. (NASDAQ:ECTE) concerning possible violations of Delaware law. To obtain additional information about the investigation, go to:
ECTE: 1.69 (-0.21)
Echo Therapeutics Announces Final Closing of Private Placement of $5.1 Million of Convertible Notes and Warrants
PR Newswire - Wed May 04, 3:11PM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive, needle-free continuous glucose monitoring (CGM) and associated technologies, today announced the final closing of a previously announced $5,145,000 private placement financing transaction of convertible notes and warrants. As previously announced, the initial closing of $1,787,000 occurred on January 29, 2016. The second tranche of the financing, or $3,358,000, was subject to the Company obtaining shareholder approval to comply with NASDAQ listing rules. The Company attained shareholder approval at a Special Meeting of Stockholders on April 14, 2016 and the final closing occurred on May 3, 2016.
ECTE: 1.69 (-0.21)
Echo Therapeutics Announces Significant Progress in Key Development Milestones
PR Newswire - Tue May 03, 8:42AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced important advances in its next generation continuous glucose monitoring (CGM) system and its progress toward commercialization in China.
ECTE: 1.69 (-0.21)
Echo Therapeutics Announces Conference Call to Provide an Update on Corporate Milestones
PR Newswire - Thu Apr 28, 7:49AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that it will hold a conference call to provide an update on its progress on upcoming corporate milestones on Wednesday, May 4, 2016, starting at 4:30 p.m. ET.
ECTE: 1.69 (-0.21)
Echo Therapeutics Announces Voting Results of Special Meeting of Stockholders
PR Newswire - Thu Apr 14, 3:30PM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, announced that at the Special Meeting of Stockholders, held today, shareholders approved the issuance of shares of its common stock to comply with NASDAQ listing rules, in connection with the Securities Purchase Agreement, dated January 29, 2016, and other transactions, including the amendment to Company's Certificate of Designations governing the terms of its Series F Convertible Preferred Stock. Shareholder approval at the special meeting was required for the $3,358,000 second closing of the previously announced $5,145,000 private placement financing transaction. As previously announced, the initial closing of $1,787,000 occurred on January 29, 2016.
ECTE: 1.69 (-0.21)
Echo Therapeutics, Inc. Announces 2015 Financial Results
PR Newswire - Wed Mar 30, 4:55PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced its financial results for the year ended December 31, 2015. Echo's Annual Report on Form 10-K, as filed with the SEC, may be accessed on the SEC's website, www.sec.gov.
ECTE: 1.69 (-0.21)
Blood Glucose Testing and Diabetes Management Study 2015
M2 - Tue Feb 02, 10:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/m5ttq8/blood_glucose) has announced the addition of the "Blood Glucose Testing and Diabetes Management" report to their offering. The report has made a survey of selected companies marketing, manufacturing or developing various blood glucose testing and diabetes management supplies throughout the world. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes, among adults across the world. As such, the global market for blood glucose testing products is undergoing a significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, certain segments of the market, such as home testing devices for diabetes management, will exhibit strong growth. What's more, non-invasive testing now represents a major new area for the application of IVD testing. Additionally, direct access testing - or over-the-counter testing, which allows consumers to order tests themselves without visiting a doctor - has emerged as a strong force in the blood glucose testing segment. The purpose of this report is to describe the specific market segments for blood glucose testing and diabetes management. This study reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum or plasma or whole-blood glucose concentrations. Moreover, it examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations. Key Topics Covered: 1. Overview 2. Diabetes 2.1 Demographics of Diabetes 2.2 Understanding the Metabolic Conditions Underlying and Associated with Diabetes 2.3 Economics of Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 3.1 Worldwide Glucose Testing Market 3.2 U.S. Market 3.3 European Market 3.4 Asian Market 3.5 Competitive Situation 3.6 Market Drivers and Restraints 3.7 Market and Product Trends 3.8 Strategic Recommendations 3.9 Competitive Strategies 3.10 New Opportunities in the Professional Blood Glucose Meter Market 3.11 Adjacent Markets 4. Glucose Diagnostic and Monitoring Recommendations 4.1 Diagnosis of Diabetes Mellitus 4.2 Tight Glucose Control in Treating Diabetes 4.3 Recommendations for Glucose Control in Diabetic Patients 4.4 Hypoglycemia and Treatment 5. Glucose Testing Technology Platforms and Consumable Products 5.1 Types of Glucose Determination Technologies 5.2 Enzymatic Reactions Used to Determine Glucose Concentrations 5.3 Development of Blood Glucose Monitors: A Historical Evaluation 5.4 Accuracy and Precision in Glucose Meters 5.5 Key Issues for Glucose Testing Devices 5.6 Limitations of Existing Glucose Testing 5.7 Potential Areas of Improvement in Blood Glucose Meter Performance 5.8 Blood Glucose Reagent Test Strips 5.9 Comparison of Hand-Held Blood Glucose Meters with Clinical Laboratory Glucose Measurements 5.10 Continuous Glucose Monitoring Technology 5.11 Summary of Technologies Being Explored for Non-invasive Glucose Monitoring 5.12 A1c Monitoring Technology 5.13 Fructosamine Test 5.14 Related Reagents and Equipment 6. Glucose Testing Devices on the Market 6.1 Hand-Held Blood Glucose Meters and Strips for Self-testing 6.2 Point of Care Blood Glucose Meters for Professional Use 6.3 Clinical Blood Chemistry Analyzers 6.4 Continuous Glucose Patient Monitoring Systems 6.5 Non-Invasive Glucose Patient Monitoring Systems 6.6 A1c Testing 6.7 New Product Launches 6.8 Blood Glucose Meters, CGMs, and Data Management Software in Development 6.9 Recent Industry Activity 6.10 M&A Activity 7. Business Trends in Glucose Testing 7.1 Drivers of Clinical Glucose Testing 7.2 Competition for Professional POC Glucose Testing 7.3 Healthcare Cost Controls 7.4 Changes in Patient Management 7.5 Regionalization of Laboratory Care 7.6 Satellite Facilities 7.7 Professional Point-of-Care Testing 7.8 Factors Affecting OTC Medical Product Distribution 7.9 Drug Stores Critical to the Diabetic Care Category 7.10 Drivers of OTC and Self-Testing Markets 7.11 Cost Elements of Glucose Self-Testing 7.12 Costs of Doing Business in Europe 7.13 Drivers of European Diagnostics Testing 7.14 Cost Containment in Europe 7.15 Blood Glucose Self-Testing Insurance Coverage and Reimbursement 7.15.1 American OTC Testing and Self-Testing Reimbursement 7.15.2 European Reimbursement 7.16 Reimbursement Challenges 7.16.1 New Medicare Part B 7.17 Managed Care 7.18 Government Regulation of Medical Devices 7.18.1 U.S. Regulations 7.18.2 E.U. Regulations 7.18.3 U.K. Regulations 7.19 Clinical Laboratory Improvement Act (CLIA) 7.19.1 Off-Label/Modified Use of Waived Blood Glucose Monitoring Systems 7.20 FDA Labeling Requirements 7.21 Legal Liability for Glucose Meters 7.22 FDA's Artificial Pancreas Guidance Document 8. Technology Trends 8.1 Improving Today's Over-The-Counter (OTC) Blood Glucose Meters 8.2 Biosensor Technology 8.3 Artificial Pancreas 8.4 Telemedicine 8.5 Non-Traditional Methods for Sample Collection 8.6 Data Management Companies Mentioned - A. Menarini Diagnostics - 9.2 Abaxis, Inc. - Abbott Laboratories - ACON Laboratories - AgaMatrix - Alere - All Medicus - AMS Alliance - Apex Biotechnology Corporation - ARKRAY USA - Bayer - B. Braun Melsungen - Beckman Coulter - Bionime - Bio-Rad Laboratories, Inc. - Cambridge Sensors - Cardiocom - DexCom - Diagnostic Devices/Prodigy Diabetes Care - DiaSys - Diatron - Echo Therapeutics - Entra Health Systems - Fora Care - FIFTY50 Medical, Inc. - Genesis Health Technologies - GenExel-Sein - GlucoPlus - GlySens - Hainice Medical - HemoCue (a Quest Diagnostics company) - Home Diagnostics - Infopia - IN4 Technology - Integrity Applications - International Techidyne Corporation (ITC) - Instrumentation Laboratory Company - i-Sens - Jant Pharmacal - Johnson & Johnson - LabStyle Innovations Corporation - LifeHealth, LLC - Medtronic - Miraculins - Nipro Diagnostics - Nova Biomedical - Polymer Technology Systems - Prodigy Diabetes Care, LLC (formerly Diagnostic Devices, Inc.) - Radiometer Medical - Roche Diagnostics - Senseonics - 77 Elektronika Kft. - Siemens AG - Smiths Group - TaiDoc Technology - Techno Medica Co., Ltd. - Telcare - Tokyo Boeki Medisys - US Diagnostics - Ypsomed Holding - YSI Life Sciences For more information visit http://www.researchandmarkets.com/research/m5...od_glucose About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 38.74 (+1.01), MDT: 84.26 (-0.33), ECTE: 1.69 (-0.21), JNJ: 116.46 (+0.28)
Echo Therapeutics expects up to USD5.1m from sale of convertible notes and warrants
M2 - Tue Feb 02, 3:26AM CST
Medical device company Echo Therapeutics (NasdaqCM:ECTE) reported on Monday the planned sale of up to USD5.145m of secured convertible notes and warrants to purchase common stock in two tranches under a Securities Purchase Agreement with certain institutional and other accredited investors.
ECTE: 1.69 (-0.21)
Echo Therapeutics Announces Entry Into Definitive Agreements for the Sale of up to $5.1 Million of Convertible Notes and Warrants
PR Newswire - Mon Feb 01, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that it entered into a Securities Purchase Agreement with certain institutional and other accredited investors for the sale of up to $5,145,000 of secured convertible notes and warrants to purchase common stock in two tranches. The initial closing of $1,787,000 occurred on January 29, 2016. The second closing of $3,358,000 is subject to shareholder approval. Certain previously issued short-term bridge notes were surrendered as payment of the initial closing purchase price.
ECTE: 1.69 (-0.21)
World Glucose Self-Testing Markets 2016 - Undergoing a Significant Transition Driven by the Advent of New Analytical Technologies
M2 - Wed Jan 13, 6:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/x53b9f/world_glucose) has announced the addition of the "World Glucose Self-Testing Markets" report to their offering. The worldwide incidence of diabetes is dramatically increasing, and it is estimated that 439 million people will have developed the disease by 2030. As such, the global market for blood glucose self-testing products is undergoing a significant transition driven by the advent of new analytical technologies and new recommendations for tight glucose control for monitoring diabetes. In addition, the proliferation of the middle class within developing nations, particularly China and India, has resulted in both a substantial rise in Type 2 diabetes and the financial means to manage the disease. The purpose of this report is to provide a comprehensive analysis of the specific segment of the over-the-counter diagnostics sector known as the glucose self-testing market. The term "self-testing" is used to distinguish it from in vitro diagnostics testing for blood glucose in hospitals, commercial labs and doctor's offices, the so-called "professional" component of the glucose testing market. This study reviews the viable technology drivers and assesses the market dynamics of the glucose self-testing market worldwide. This report also looks at the industry challenges and potential threats, and it makes strategic recommendations for boosting market share. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Self-Testing Technology Platforms and Consumable Products 6. Glucose Self-Testing Meters on the Market: Description of Test Meters 7. Business Trends in the Industry 8. Technology Trends 9. OTC Testing: Critical Issues 10. Current Issues for OTC and Diagnostic Self-Testing 11. SWOT Analysis 12. Company Profiles Companies Mentioned - 77 Elektronika Kft. - A. Menarini Diagnostics - ACON Laboratories - ARKRAY USA, Inc. - Abbott Laboratories - AgaMatrix - Allmedicus Co., Ltd. - Apex Biotechnology Corporation - B. Braun Melsungen - Bayer - Bionime - Cambridge Sensors - Cardiocom - DexCom - Diagnostic Devices/Prodigy Diabetes Care - Echo Therapeutics, Inc. - Entra Health Systems - FIFTY50 Medical, Inc. - Fora Care - Genesis Health Technologies - GlucoPlus - GlySens, Inc. - Google - Hainice Medical - Home Diagnostics - IN4 Technology - Infopia - Integrity Applications - Johnson & Johnson - LabStyle Innovations Corporation - Livongo Health - Medtronic - Miraculins - Nipro Corporation For more information visit http://www.researchandmarkets.com/research/x5...ld_glucose
ECTE: 1.69 (-0.21), JNJ: 116.46 (+0.28), ABT: 38.74 (+1.01), MDT: 84.26 (-0.33)
U.S. Glucose Testing Markets 2016 - Direct Access Testing has Emerged as a Strong Force in the Blood Glucose Testing Segment
M2 - Wed Jan 13, 5:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/p425rm/u_s_glucose) has announced the addition of the "U.S. Glucose Testing Markets" report to their offering. U.S. glucose testing is undergoing a significant transition, driven by new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, several segments of the market, such as home testing devices for diabetes management and point of care (POC) instruments for use in professional settings, will exhibit strong growth. Direct access testing has emerged as a strong force in the blood glucose testing segment, and non-invasive and minimally-invasive testing now represent major new areas for the application of IVD testing. This report describes the specific market segments for blood glucose testing and diabetes management in the U.S. market. It reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum, plasma or whole-blood glucose concentrations. Additionally, this study examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations. Moreover, it analyzes almost all of the companies known to be marketing, manufacturing or developing glucose testing products for the U.S. market. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Testing Technology Platforms and Consumable Products 6. Glucose Testing Devices on the Market 7. Business Trends in Glucose Testing 8. Technology Trends 9. Company Profiles Companies Mentioned - Abaxis, Inc. - Abbott Laboratories - ACON Laboratories - AgaMatrix - Alere - Allmedicus - Amedica Biotech - A. Menarini Diagnostics - Apex Biotechnology Corporation - Arkray - Bayer - B. Braun Melsungen - Beckman Coulter - Bionime - Bio-Rad Laboratories, Inc. - BioTex - Calisto Medical - Cambridge Sensors - DexCom - Diagnostic Devices/Prodigy Diabetes Care - DiaSys - Echo Therapeutics - Entra Health Systems - Fora Care - Freedom Meditech - Genesis Health Technologies - GenExel-Sein - GlucoPlus - GluMetrics - GlySens - GlySure Limited - Grove Instruments For more information visit http://www.researchandmarkets.com/research/p4..._s_glucose
ECTE: 1.69 (-0.21), ABT: 38.74 (+1.01), ABAX: 45.30 (-0.68)
Echo Therapeutics Appoints Elazer Edelman, M.D., Ph.D. to Board of Directors
PR Newswire - Mon Dec 28, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced the appointment of Elazer Edelman, M.D., Ph.D. to its Board of Directors. Currently a professor at MIT and Harvard Medical School, Dr. Edelman is widely recognized for his vision, leadership and significant, long-term contribution to the advancement of technological innovation. Dr. Edelman brings to Echo Therapeutics over 30 years experience in facilitating medical inventions and clinical implementation.
ECTE: 1.69 (-0.21)
The Global Glucose Monitoring Market
M2 - Mon Dec 14, 7:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/gnkzld/the_global) has announced the addition of the "The Global Glucose Monitoring Market" report to their offering. There are many issues facing this industry. Some issues are helping to propel the market; while other issues are retarding growth forward. Issues and trends driving the market for glucose monitoring devices and diabetes management include: - New innovations - Reimbursement challenges - Recalls - Aging of the population - Increasing life expectancy - Healthcare spending trends - Advances in sensors - Health insurance portability - Cost cutting - Healthcare efficiency - Capacity challenges - Growing acceptance of mobile technologies - Other factors. These are discussed at length in the report, as are their role in market growth. In this global report, Kalorama identifies market size and forecast for Traditional Glucose Monitoring and Continuous Glucose Monitoring (CGM) both worldwide and for the following countries and regions: - United States - Germany - France - Italy - UK - Japan - Brazil - Russia - India - China Companies Included: - Abbott Laboratories - AgaMatrix - Arkray, Inc - Bayer Diabetes - Bionime Corporation - DexCom, Inc. - Echo Therapeutics - Entra Health Systems LLC - Fora Care, Inc - Genesis Health Technologies - GlySure Limited - Insulet - Johnson & Johnson - Medtronic - Nipro Diagnostics, Inc - Nova Diabetes Care, Inc. - Oak Tree International Holdings, Inc. - Prodigy Diabetes Care, LLC Roche - U.S. Diagnostics, Inc. Key Topics Covered: Chapter 1 - List of Contributors and Exhibits Chapter 2 - Executive Summary Chapter 3 - Introduction Chapter 4 - Traditional Glucose Monitoring Devices and Diabetes Chapter 5 - Management Market Chapter 6 - Continuous Glucose Monitoring and Sensor Market Chapter 7 - Issues and Trends Chapter 8 - Global Glucose Monitoring Devices and Diabetes Chapter 9 - Management Market and Competitor Analysis Chapter 10 - Corporate Profiles For more information visit http://www.researchandmarkets.com/research/gnkzld/the_global
ECTE: 1.69 (-0.21), JNJ: 116.46 (+0.28), ABT: 38.74 (+1.01), DXCM: 77.49 (-0.02), MDT: 84.26 (-0.33)
Echo Therapeutics, Inc. Announces Third Quarter 2015 Financial Results and Provides Corporate Update
PR Newswire - Mon Nov 16, 3:40PM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced its financial results for the quarter ended September 30, 2015. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, is available by visiting the Investors section of Echo's website at www.echotx.com.
ECTE: 1.69 (-0.21)
Echo Therapeutics' Continuous Glucose Monitoring System to be Profiled on Worldwide Business with kathy ireland® - NEW DAY and TIME!
PR Newswire - Wed Oct 21, 8:27AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring and associated technologies, today announced that it was informed that, due to network scheduling issues, its President and CEO, Scott W. Hollander, is now scheduled to appear on Worldwide Business with kathy ireland, as sponsored programming, on Sunday, October 25, 2015. Echo has accepted this change because it believes that the new day and time will provide increased viewership among key demographics.
ECTE: 1.69 (-0.21)
Echo Therapeutics' Continuous Glucose Monitoring System to be Profiled on Worldwide Business with kathy ireland®
PR Newswire - Wed Oct 21, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring and associated technologies, today announced that its President and CEO, Scott W. Hollander, will appear on Worldwide Business with kathy ireland, as sponsored programming, on Saturday, October 24, 2015.
ECTE: 1.69 (-0.21)
Worldwide Business with kathy ireland Introduces the Exciting Echo Therapeutics Technology for Glucose Monitoring
BusinessWire - Tue Oct 20, 9:20AM CDT
MMP (USA) announces a Worldwide Business with kathy ireland exclusive interview with Scott Hollander, President & CEO of Echo Therapeutics, Inc. Hollander introduces his company with, "Our break-through continuous glucose monitoring system consists of three elements: A micro exfoliator, a sensor and your Smartphone as a monitor. We are applying this exciting capability in multiple markets covering the rapidly growing wearables segments, as well as the outpatient diabetes market."
ECTE: 1.69 (-0.21)
